![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/08/02/2716797/0/en/Kala-Pharmaceuticals-Announces-Name-Change-to-KALA-BIO.html
https://www.globenewswire.com/news-release/2023/07/19/2707717/0/en/Kala-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2023/06/23/2693902/0/en/Kala-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2023/06/02/2681101/0/en/Kala-Pharmaceuticals-to-Present-at-the-Jefferies-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2023/05/09/2664373/0/en/Kala-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2023/04/12/2645285/0/en/Kala-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-KPI-012-a-Human-MSC-S-Therapy-for-Persistent-Corneal-Epithelial-Defect.html
https://www.globenewswire.com/news-release/2023/03/29/2636607/0/en/Kala-Pharmaceuticals-Appoints-Dr-Francis-Mah-as-Chief-Medical-Advisor.html
https://investors.kalarx.com/news-releases/news-release-details/kala-pharmaceuticals-announces-positive-safety-update-cohort-1
https://www.globenewswire.com/news-release/2023/03/27/2634688/0/en/Kala-Pharmaceuticals-Announces-Positive-Safety-Update-from-Cohort-1-of-CHASE-Phase-2b-Clinical-Trial-Evaluating-KPI-012-in-Patients-with-PCED.html
https://investors.kalarx.com/news-releases/news-release-details/kala-pharmaceuticals-present-oppenheimer-33rd-annual-healthcare